ClinicalTrials.gg
TerminatedNCT03896295Updated Jun 27, 2023Results posted

An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

A Phase 2 interventional study of M281 in Generalized Myasthenia Gravis, sponsored by Momenta Pharmaceuticals, Inc.. Terminated at 54 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-27.

Sponsored by Momenta Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was originally halted due to the COVID-19 pandemic. The study was later terminated prematurely as the participants will have the option to enter into an open-label extension portion of a planned future study. It was not due to safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Enrollment
64th of 108
37 · median 56
Started
2019
with 13 others
Phase 2
26 of 144
5 open now
Registered
42nd of 144
by date

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 64th largest by enrollment of the 108 interventional ones that give a count, is one of 14 that started in 2019, is one of 26 in phase 2, and was the 42nd registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and tolerability of M281 in participants with generalized myasthenia gravis (gMG)

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • M281
  • Generalized Myasthenia Gravis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants must be ≥18 years of age with a documented history of Generalized Myasthenia Gravis (gMG) and clinical signs/symptoms of gMG, not pregnant or breastfeeding, previously participated in the MOM-281-004 study, had no major eligibility deviations or other major protocol deviations or not met any of the stopping criteria or discontinued study drug in the MOM-M281-004 study for any reason other than the need for rescue therapy as specified in the MOM-M281-004 study.

Additional, more specific criteria are defined in the protocol.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    M281

    Drug: M281

Interventions

  • DrugM281

    M281 injection administered as intravenous infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Number of participants with TEAEs were reported. An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as any AE occurring during or after the initiation of the first infusion of study drug in this study.

    Time frame: Up to 257 days post-baseline (Baseline is Day 1)

  2. Number of Participants With Serious Adverse Events (SAEs)

    An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is defined as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.

    Time frame: Up to 257 days post-baseline

  3. Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)

    Number of participants with treatment-emergent AESIs were reported. Severe infections and hypoalbuminemia (Grade 3 or higher according to the Common Terminology Criteria for Adverse Events \[CTCAE\] v5.0) were considered as AESIs.

    Time frame: Up to 257 days post-baseline

  4. Number of Participants With Treatment-emergent Abnormal Vital Signs

    Number of participants with treatment-emergent abnormal vital signs including pulse rate (less than or equal to \[\<=\] 50 beats per minutes \[bpm\] with greater than or equal to \[\>=\] 15 bpm decrease from baseline, \>= 120 bpm with \>=15 bpm increase from baseline), systolic blood pressure (SBP) (\<= 90 millimeters of mercury \[mmHg\] with \>= 20 mmHg decrease from baseline, \>= 160 mmHg with \>= 20 mmHg increase from baseline) and diastolic blood pressure (DBP) (\<= 50 mmHg with \>=15 mmHg decrease from baseline, \>=100 mmHg with \>=15 mmHg decrease from baseline) were reported.

    Time frame: Up to 257 days post-baseline

  5. Number of Participants With Abnormalities in Physical Examinations

    Number of participants with abnormalities in physical examinations (abdomen, head, ears, eyes, nose, throat, and sinuses, lungs, neurological, skin, blood and lymphatic system, cardiovascular, chest, gastrointestinal, general appearance and musculoskeletal) were reported.

    Time frame: Week 12

  6. Change From Baseline in Chemistry Laboratory Parameters: Albumin and Protein

    Change from baseline in chemistry laboratory parameters: albumin and protein were reported.

    Time frame: Baseline up to Week 12

  7. Change From Baseline in Chemistry Laboratory Parameters: Bicarbonate, Calcium, Chloride, Cholesterol, Glucose, Phosphate, Potassium, Sodium, Triglycerides, Urate and Urea Nitrogen

    Change from baseline in chemistry laboratory parameters: bicarbonate, calcium, chloride, cholesterol, glucose, phosphate, potassium, sodium, triglycerides, urate and urea nitrogen were reported.

    Time frame: Baseline up to Week 12

  8. Change From Baseline in Chemistry Laboratory Parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Creatine Kinase, Gamma Glutamyl Transferase, Lactate Dehydrogenase

    Change from baseline in chemistry laboratory parameters alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), creatine kinase, gamma glutamyl transferase, lactate dehydrogenase were reported.

    Time frame: Baseline up to Week 12

  9. Change From Baseline in Chemistry Laboratory Parameters: Bilirubin, Creatinine and Direct Bilirubin

    Change from baseline in chemistry laboratory parameters: bilirubin, creatinine and direct bilirubin were reported.

    Time frame: Baseline up to Week 12

  10. Change From Baseline in Hematology Laboratory Parameter: Erythrocytes (Red Blood Cell)

    Change from baseline in erythrocytes (red blood cells) (hematology laboratory parameter) was reported.

    Time frame: Baseline up to Week 12

  11. Change From Baseline in Hematology Laboratory Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes

    Change from baseline in hematology laboratory parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes were reported.

    Time frame: Baseline up to Week 12

  12. Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration

    Change from baseline in erythrocytes mean corpuscular hemoglobin (HGB) concentration (hematology laboratory parameter) were reported.

    Time frame: Baseline up to Week 12

  13. Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin (HGB)

    Change from baseline in erythrocytes mean corpuscular HGB (hematology laboratory parameter) was reported.

    Time frame: Baseline up to Week 12

  14. Change From Baseline in Hematology Laboratory Parameter: Erythrocytes Mean Corpuscular Volume

    Change from baseline in erythrocytes mean corpuscular volume (hematology laboratory parameter) was reported.

    Time frame: Baseline up to Week 12

  15. Change From Baseline in Hematology Laboratory Parameter: Hematocrit

    Change from baseline in hematocrit (hematology laboratory parameter) was reported.

    Time frame: Baseline up to Week 12

  16. Change From Baseline in Hematology Laboratory Parameter: Hemoglobin

    Change from baseline in hemoglobin (hematology laboratory parameter) was reported.

    Time frame: Baseline up to Week 12

  17. Change From Baseline in Urinalysis Laboratory Parameter: pH

    Change from baseline in pH (urinalysis laboratory parameter) was reported.

    Time frame: Baseline up to Week 12

  18. Change From Baseline in Urinalysis Laboratory Parameter: Specific Gravity

    Change from baseline in specific gravity (urinalysis laboratory parameter) was reported.

    Time frame: Baseline up to Week 12

  19. Number of Participants With Treatment-emergent Abnormal Electrocardiograms (ECG) Values

    Number of participants with treatment-emergent abnormal ECG values for variables including mean heart rate (abnormally low refers to less than or equal to \[\<=\] 50 beats per minute \[bpm\], abnormally high refers greater than or equal to \[\>=\] 120 bpm), PR interval (abnormally low refers to \< 120 and abnormally high refers to \>200 milliseconds \[msec\]), RR interval (abnormally low refers to \<600 msec and abnormally high refers to \>1200 msec) and QRS duration (abnormally \> 120) were reported.

    Time frame: Up to 257 days post-baseline

  20. Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Scores

    Number of participants with C-SSRS scores were reported. C-SSRS is a clinician-administered questionnaire designed to solicit occurrence, severity, and frequency of suicide-related ideation and behaviors. Total score ranges from 1 to 10, score of 0 was assigned (0="no event that can be assessed based on C-SSRS"). Higher total scores indicate greater severity. Maximum score assigned for each participant was summarized into one of 3 categories: no suicidal ideation or behavior (0), suicidal ideation (1 to 5): higher score indicates more suicidal ideation, suicidal behavior (6 to 10): higher score indicates more suicidal behavior. Suicidal ideation includes participants who did not have suicidal ideation or behavior at baseline and had suicidal ideation without behavior at some time point post-baseline. Suicidal behavior includes participants who did not have suicidal ideation or behavior at baseline and had suicidal behavior at some time point post-baseline (baseline=Day 1).

    Time frame: Up to 257 days post-baseline

  21. Number of Participants With Below/Above Normal Values of Coagulation Laboratory Parameter

    Number of participants with at least one value above upper limit of normal (\>ULN) or below the lower limit of normal (\< LLN) value of coagulation parameters (activated partial thromboplastin time \[APTT\] and prothrombin time \[PT\]) were reported. The lab reference range for APTT is 25.1 to 36.5 seconds. The lab reference range for PT is 9.4 to 12.5 seconds.

    Time frame: Up to 257 days post-baseline

Secondary outcomes

  1. Change From Baseline in Total Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score Over Time

    The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.

    Time frame: Baseline up to Weeks 4, 8, 12, 24, End of treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)

  2. Number of Participants With a 2-, 3-, 4-, 5-, 6-, 7-, or Greater Than or Equal to (>=) 8-point Improvement in Total MG-ADL Score Over Time

    Number of Participants With a 2-, 3-, 4-, 5-, 6-, 7-, or greater than or equal to (\>=) 8-point improvement in total MG-ADL score over time were reported. MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.

    Time frame: Weeks 4, 8, 12, 24, End of treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)

  3. Change From Baseline in Total Quantitative Myasthenia Gravis (QMG) Score Over Time

    The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.

    Time frame: Baseline up to Weeks 4, 8, 12, 24, End of Treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)

  4. Change From Baseline in Total Revised Myasthenia Gravis Quality of Life - 15 Scale (MG-QoL15r) Score Over Time

    The MG-QoL15r was used to assess the participant's limitations related to living with MG. It consists of 15 questions and each of the 15 questions were rated by the participant on a 3-point scale (0= Not at all, 1= somewhat, 2=very much) based on a recall period of "over the past few weeks". The total score is the sum of the 15 question scores and ranges from 0 to 30. Higher scores indicated more limitation.

    Time frame: Baseline up to Weeks 4, 8, 12, 24, End of Treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)

  5. Change From Baseline in Clinical Global Impression of Severity (CGI-S) Rating Score Over Time

    The CGI-S scale is the clinician/physician's global assessment of participants illness severity of MG and is rated by answering on 8-point scale. Considering total clinical experience, participant is assessed on severity of illness according to: 0=not performed; 1=normal, not at all ill; 2=borderline illness; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. Higher scores indicated more severity of illness. Values of 0 (not assessed) were excluded from analysis. CGI-S permits global evaluation of participant's condition at given time.

    Time frame: Baseline up to Weeks 4, 8, 12, 24, End of Treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)

  6. Number of Participants With Improvement of Illness Over Time Based on Clinical Global Impression of Improvement (CGI-I) Scale Score

    Number of participants with improvement of illness based on CGI-I scale score over time were reported. The CGI-I scale is the clinician/physician's global assessment of the change in severity of the patient's generalized myasthenia gravis (gMG) since starting this study. The rating is given on a 7-point scale with lower scores indicating greater improvement (1= Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 =Minimally worse; 6 = Much worse; 7 = Very much worse. Values of 0 (not assessed) were excluded from analysis. Higher score indicates more severity.

    Time frame: Weeks 4, 8, 12, 24, End of Treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)

  7. Number of Participants With Change From Baseline in Myasthenia Gravis Foundation of America (MGFA) Classification Score Over Time

    Number of participants with change from baseline in MGFA classification score over time were reported. The MGFA was used to assess the participant's MG severity. MGFA classification identifies the subgroup participants with MG who share distinct clinical features or severity of disease: Class I (ocular MG), classes II, III and IV generalized MG with mild, moderate and severe disease, respectively; Class V MG crisis. Separate subclasses under classes II, III and IV are designed: "a" if the predominant weakness is affecting limb/axial weakness or both; subclass "b" if the predominant weakness is affecting oropharyngeal or respiratory muscles or both. In the MGFA classification, lower roman numerals mean less severity. Changes in MGFA classification (regardless of subclass) are categorized as "Improved" (example, III to II), "Same" (example, II to II), or "Worsened" (example, II to III).

    Time frame: Weeks 8, 24 and End of Treatment (EoT) (up to 253 days post-baseline)

  8. Number of Participants With Anti-drug Antibodies (ADA) to Nipocalimab

    Number of participants with ADA to nipocalimab were reported. The presence of ADA to nipocalimab in serum was determined by a sensitive and drug-tolerant electrochemiluminescence immunoassay (ECLIA) method.

    Time frame: Up to 257 days post-baseline

  9. Number of Participants With Neutralizing Antibodies (NAbs) to Nipocalimab

    Number of participants with NAbs were reported. Neutralizing antibodies to nipocalimab were assessed using a non-cell based competitive ligand binding ECLIA assay.

    Time frame: Up to 257 days post-baseline

  10. Change From Baseline in Serum Immunoglobulin (Ig)G Concentration Over Time

    Change from baseline in serum immunoglobulin (Ig)G concentration over time was reported.

    Time frame: Baseline to Weeks 2, 4, 8, 12, 24, up to 253 days post-baseline, up to 257 days post-baseline

07

Results

Posted Feb 16, 2022
Limitations and caveats
Study was originally halted due to the COVID-19 pandemic. The study was later terminated prematurely due to the continuing COVID-19 pandemic, and because the participants will have the option to enter into an open-label extension portion of a planned future study. It was not due to safety concerns.

Participant flow

Participant flow — Overall Study
MilestonePlacebo-NipocalimabNipocalimab-Nipocalimab
Started730
Completed00
Not completed730
Withdrew: Adverse event01
Withdrew: Covid-19729

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

Number of participants with TEAEs were reported. An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as any AE occurring during or after the initiation of the first infusion of study drug in this study.

Time frame:
Up to 257 days post-baseline (Baseline is Day 1)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)41822
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is defined as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.

Time frame:
Up to 257 days post-baseline
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Number of Participants With Serious Adverse Events (SAEs)145
PrimaryNumber of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)

Number of participants with treatment-emergent AESIs were reported. Severe infections and hypoalbuminemia (Grade 3 or higher according to the Common Terminology Criteria for Adverse Events \[CTCAE\] v5.0) were considered as AESIs.

Time frame:
Up to 257 days post-baseline
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)
ParticipantsPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)112
PrimaryNumber of Participants With Treatment-emergent Abnormal Vital Signs

Number of participants with treatment-emergent abnormal vital signs including pulse rate (less than or equal to \[\<=\] 50 beats per minutes \[bpm\] with greater than or equal to \[\>=\] 15 bpm decrease from baseline, \>= 120 bpm with \>=15 bpm increase from baseline), systolic blood pressure (SBP) (\<= 90 millimeters of mercury \[mmHg\] with \>= 20 mmHg decrease from baseline, \>= 160 mmHg with \>= 20 mmHg increase from baseline) and diastolic blood pressure (DBP) (\<= 50 mmHg with \>=15 mmHg decrease from baseline, \>=100 mmHg with \>=15 mmHg decrease from baseline) were reported.

Time frame:
Up to 257 days post-baseline
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Abnormal Vital Signs
ParticipantsPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Pulse rate: <=50 bpm with >=15 bpm decrease from baseline000
Pulse rate: >= 120 bpm with >=15 bpm increase from baseline000
SBP: <= 90 mmHg with >= 20 mmHg decrease from baseline011
SBP: >= 160 mmHg with >= 20 mmHg increase from baseline011
DBP: <= 50 mmHg with >=15 mmHg decrease from baseline022
DBP: >=100 mmHg with >=15 mmHg decrease from baseline000
PrimaryNumber of Participants With Abnormalities in Physical Examinations

Number of participants with abnormalities in physical examinations (abdomen, head, ears, eyes, nose, throat, and sinuses, lungs, neurological, skin, blood and lymphatic system, cardiovascular, chest, gastrointestinal, general appearance and musculoskeletal) were reported.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Physical Examinations
ParticipantsPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Abdomen101
Head, Ears, Eyes, Nose, Throat and Sinuses000
Lungs000
Neurological011
Skin145
PrimaryChange From Baseline in Chemistry Laboratory Parameters: Albumin and Protein

Change from baseline in chemistry laboratory parameters: albumin and protein were reported.

Time frame:
Baseline up to Week 12
Reported as:
Mean · grams per liter (g/L)
Change From Baseline in Chemistry Laboratory Parameters: Albumin and Protein
grams per liter (g/L)Placebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Albumin-1.5 ± 2.89-1.2 ± 3.21-1.3 ± 3.08
Protein-3.5 ± 2.08-3.8 ± 4.99-3.7 ± 4.54
PrimaryChange From Baseline in Chemistry Laboratory Parameters: Bicarbonate, Calcium, Chloride, Cholesterol, Glucose, Phosphate, Potassium, Sodium, Triglycerides, Urate and Urea Nitrogen

Change from baseline in chemistry laboratory parameters: bicarbonate, calcium, chloride, cholesterol, glucose, phosphate, potassium, sodium, triglycerides, urate and urea nitrogen were reported.

Time frame:
Baseline up to Week 12
Reported as:
Mean · millimoles per liter (mmol/L)
Change From Baseline in Chemistry Laboratory Parameters: Bicarbonate, Calcium, Chloride, Cholesterol, Glucose, Phosphate, Potassium, Sodium, Triglycerides, Urate and Urea Nitrogen
millimoles per liter (mmol/L)Placebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Bicarbonate-2.0 ± 2.451.6 ± 2.911.0 ± 3.14
Calcium0.010 ± 0.0627-0.018 ± 0.1005-0.013 ± 0.0938
Chloride0.5 ± 1.910.6 ± 2.850.6 ± 2.66
Cholesterol0.480 ± 1.01000.261 ± 0.57320.303 ± 0.6509
Glucose0.280 ± 0.5054-0.258 ± 1.1401-0.155 ± 1.0607
Phosphate-0.018 ± 0.0971-0.002 ± 0.1903-0.005 ± 0.1744
Potassium0.05 ± 0.1730.05 ± 0.5830.05 ± 0.526
Sodium0.8 ± 0.961.4 ± 2.181.2 ± 2.00
Triglycerides0.223 ± 0.57990.081 ± 0.32230.108 ± 0.3699
Urate-0.0090 ± 0.042850.0174 ± 0.047900.124 ± 0.04716
Urea Nitrogen-0.270 ± 1.7830-0.105 ± 1.7292-0.136 ± 1.6951
PrimaryChange From Baseline in Chemistry Laboratory Parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Creatine Kinase, Gamma Glutamyl Transferase, Lactate Dehydrogenase

Change from baseline in chemistry laboratory parameters alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), creatine kinase, gamma glutamyl transferase, lactate dehydrogenase were reported.

Time frame:
Baseline up to Week 12
Reported as:
Mean · units per liter (U/L)
Change From Baseline in Chemistry Laboratory Parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Creatine Kinase, Gamma Glutamyl Transferase, Lactate Dehydrogenase
units per liter (U/L)Placebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
ALT17.0 ± 28.762.6 ± 5.335.3 ± 13.43
Alkaline Phosphatase6.3 ± 2.065.2 ± 11.465.4 ± 10.23
AST23.5 ± 47.670.9 ± 3.425.2 ± 20.80
Creatine Kinase-17.8 ± 33.1313.6 ± 38.347.7 ± 38.73
Gamma Glutamyl Transferase4.3 ± 11.951.5 ± 13.212.0 ± 12.74
Lactate Dehydrogenase30.0 ± 15.6830.9 ± 58.1030.7 ± 52.00
PrimaryChange From Baseline in Chemistry Laboratory Parameters: Bilirubin, Creatinine and Direct Bilirubin

Change from baseline in chemistry laboratory parameters: bilirubin, creatinine and direct bilirubin were reported.

Time frame:
Baseline up to Week 12
Reported as:
Mean · micromoles per liter (micromol/L)
Change From Baseline in Chemistry Laboratory Parameters: Bilirubin, Creatinine and Direct Bilirubin
micromoles per liter (micromol/L)Placebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Bilirubin0.13 ± 2.616-0.59 ± 2.403-0.46 ± 2.393
Creatinine-9.0 ± 7.35-2.6 ± 13.20-3.9 ± 12.41
Direct Bilirubin-1.20 ± NA-0.70 ± 0.283-0.87 ± 0.359
PrimaryChange From Baseline in Hematology Laboratory Parameter: Erythrocytes (Red Blood Cell)

Change from baseline in erythrocytes (red blood cells) (hematology laboratory parameter) was reported.

Time frame:
Baseline up to Week 12
Reported as:
Mean · 10^12 cells count per Liter
Change From Baseline in Hematology Laboratory Parameter: Erythrocytes (Red Blood Cell)
10^12 cells count per LiterPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Change From Baseline in Hematology Laboratory Parameter: Erythrocytes (Red Blood Cell)0.188 ± 0.08220.121 ± 0.27020.135 ± 0.2438
PrimaryChange From Baseline in Hematology Laboratory Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes

Change from baseline in hematology laboratory parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes were reported.

Time frame:
Baseline up to Week 12
Reported as:
Mean · 10^9 cells count per Liter
Change From Baseline in Hematology Laboratory Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
10^9 cells count per LiterPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Basophils-0.003 ± 0.01500.010 ± 0.02000.006 ± 0.0188
Eosinophils0.015 ± 0.04650.013 ± 0.07760.014 ± 0.0702
Lymphocytes-0.045 ± 0.44980.063 ± 0.47150.041 ± 0.4576
Monocytes-0.105 ± 0.19640.059 ± 0.20080.027 ± 0.2061
Neutrophils-0.433 ± 0.57440.411 ± 1.86220.243 ± 1.7058
Platelets27.8 ± 11.8112.3 ± 53.2015.4 ± 47.93
Leukocytes-0.568 ± 0.92140.567 ± 1.99560.340 ± 1.8694
PrimaryChange From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration

Change from baseline in erythrocytes mean corpuscular hemoglobin (HGB) concentration (hematology laboratory parameter) were reported.

Time frame:
Baseline up to Week 12
Reported as:
Mean · grams per Liter (g/L)
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration
grams per Liter (g/L)Placebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration-6.5 ± 25.70-2.1 ± 7.61-3.0 ± 12.38
PrimaryChange From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin (HGB)

Change from baseline in erythrocytes mean corpuscular HGB (hematology laboratory parameter) was reported.

Time frame:
Baseline up to Week 12
Reported as:
Mean · picograms (pg)
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin (HGB)
picograms (pg)Placebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin (HGB)0.03 ± 0.873-0.61 ± 0.813-0.48 ± 0.842
PrimaryChange From Baseline in Hematology Laboratory Parameter: Erythrocytes Mean Corpuscular Volume

Change from baseline in erythrocytes mean corpuscular volume (hematology laboratory parameter) was reported.

Time frame:
Baseline up to Week 12
Reported as:
Mean · femtoliters (fL)
Change From Baseline in Hematology Laboratory Parameter: Erythrocytes Mean Corpuscular Volume
femtoliters (fL)Placebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Change From Baseline in Hematology Laboratory Parameter: Erythrocytes Mean Corpuscular Volume2.45 ± 6.174-1.41 ± 3.406-0.64 ± 4.206
PrimaryChange From Baseline in Hematology Laboratory Parameter: Hematocrit

Change from baseline in hematocrit (hematology laboratory parameter) was reported.

Time frame:
Baseline up to Week 12
Reported as:
Mean · liter of cells per liter of blood (L/L)
Change From Baseline in Hematology Laboratory Parameter: Hematocrit
liter of cells per liter of blood (L/L)Placebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Change From Baseline in Hematology Laboratory Parameter: Hematocrit0.0278 ± 0.035420.0048 ± 0.024010.0094 ± 0.02725
PrimaryChange From Baseline in Hematology Laboratory Parameter: Hemoglobin

Change from baseline in hemoglobin (hematology laboratory parameter) was reported.

Time frame:
Baseline up to Week 12
Reported as:
Mean · g/L
Change From Baseline in Hematology Laboratory Parameter: Hemoglobin
g/LPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Change From Baseline in Hematology Laboratory Parameter: Hemoglobin5.8 ± 4.650.6 ± 7.291.7 ± 7.06
PrimaryChange From Baseline in Urinalysis Laboratory Parameter: pH

Change from baseline in pH (urinalysis laboratory parameter) was reported.

Time frame:
Baseline up to Week 12
Reported as:
Mean · pH
Change From Baseline in Urinalysis Laboratory Parameter: pH
pHPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Change From Baseline in Urinalysis Laboratory Parameter: pH-0.8 ± 0.960.0 ± 1.06-0.1 ± 1.06
PrimaryChange From Baseline in Urinalysis Laboratory Parameter: Specific Gravity

Change from baseline in specific gravity (urinalysis laboratory parameter) was reported.

Time frame:
Baseline up to Week 12
Reported as:
Mean · ratio
Change From Baseline in Urinalysis Laboratory Parameter: Specific Gravity
ratioPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Change From Baseline in Urinalysis Laboratory Parameter: Specific Gravity-0.0003 ± 0.00660-0.0030 ± 0.00973-0.0025 ± 0.00914
PrimaryNumber of Participants With Treatment-emergent Abnormal Electrocardiograms (ECG) Values

Number of participants with treatment-emergent abnormal ECG values for variables including mean heart rate (abnormally low refers to less than or equal to \[\<=\] 50 beats per minute \[bpm\], abnormally high refers greater than or equal to \[\>=\] 120 bpm), PR interval (abnormally low refers to \< 120 and abnormally high refers to \>200 milliseconds \[msec\]), RR interval (abnormally low refers to \<600 msec and abnormally high refers to \>1200 msec) and QRS duration (abnormally \> 120) were reported.

Time frame:
Up to 257 days post-baseline
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Abnormal Electrocardiograms (ECG) Values
ParticipantsPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
ECG Mean Heart Rate (<= 50)055
ECG Mean Heart Rate (>=120)000
PR Interval (<120)000
PR Interval (> 200)055
RR Interval (<600)000
RR Interval (>=1200)044
QRS Duration (>120)134
PrimaryNumber of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Scores

Number of participants with C-SSRS scores were reported. C-SSRS is a clinician-administered questionnaire designed to solicit occurrence, severity, and frequency of suicide-related ideation and behaviors. Total score ranges from 1 to 10, score of 0 was assigned (0="no event that can be assessed based on C-SSRS"). Higher total scores indicate greater severity. Maximum score assigned for each participant was summarized into one of 3 categories: no suicidal ideation or behavior (0), suicidal ideation (1 to 5): higher score indicates more suicidal ideation, suicidal behavior (6 to 10): higher score indicates more suicidal behavior. Suicidal ideation includes participants who did not have suicidal ideation or behavior at baseline and had suicidal ideation without behavior at some time point post-baseline. Suicidal behavior includes participants who did not have suicidal ideation or behavior at baseline and had suicidal behavior at some time point post-baseline (baseline=Day 1).

Time frame:
Up to 257 days post-baseline
Reported as:
Count of participants · Participants
Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Scores
ParticipantsPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
No Suicidal Ideation/Behavior53035
Suicidal Ideation101
Suicidal Behavior000
SecondaryChange From Baseline in Total Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score Over Time

The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.

Time frame:
Baseline up to Weeks 4, 8, 12, 24, End of treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)
Reported as:
Mean · score on a scale
Change From Baseline in Total Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score Over Time
score on a scalePlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Week 40.6 ± 1.34-0.6 ± 2.42-0.4 ± 2.30
Week 8-0.8 ± 3.70-0.9 ± 2.63-0.9 ± 2.80
Week 12-0.3 ± 4.35-1.2 ± 2.49-1.0 ± 2.82
Week 24-1.0 ± NA-1.2 ± 1.92-1.2 ± 1.72
EoT (up to 253 days post-baseline)—-2.4 ± 2.55-2.4 ± 2.55
Follow-up (up to 257 days post-baseline)-0.6 ± 1.141.2 ± 3.080.9 ± 2.91
SecondaryNumber of Participants With a 2-, 3-, 4-, 5-, 6-, 7-, or Greater Than or Equal to (>=) 8-point Improvement in Total MG-ADL Score Over Time

Number of Participants With a 2-, 3-, 4-, 5-, 6-, 7-, or greater than or equal to (\>=) 8-point improvement in total MG-ADL score over time were reported. MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.

Time frame:
Weeks 4, 8, 12, 24, End of treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)
Reported as:
Count of participants · Participants
Number of Participants With a 2-, 3-, 4-, 5-, 6-, 7-, or Greater Than or Equal to (>=) 8-point Improvement in Total MG-ADL Score Over Time
ParticipantsPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Week 4 (2 Point Improvement)—22
Week 4 (3 Point Improvement)—11
Week 4 (4 Point Improvement)—00
Week 4 (5 Point Improvement)—11
Week 4 (6 Point Improvement)—22
Week 4 (7 Point Improvement)—00
Week 4 (>= 8 Point Improvement)—00
Week 8 (2 Point Improvement)123
Week 8 (3 Point Improvement)044
Week 8 (4 Point Improvement)000
Week 8 (5 Point Improvement)000
Week 8 (6 Point Improvement)101
Week 8 (7 Point Improvement)000
Week 8 (>= 8 Point Improvement)011
Week 12 (2 Point Improvement)022
Week 12 (3 Point Improvement)000
Week 12 (4 Point Improvement)000
Week 12 (5 Point Improvement)000
Week 12 (6 Point Improvement)134
Week 12 (7 Point Improvement)000
Week 12 (>= 8 Point Improvement)000
Week 24 (2 Point Improvement)—11
Week 24 (3 Point Improvement)—00
Week 24 (4 Point Improvement)—11
Week 24 (5 Point Improvement)—00
Week 24 (6 Point Improvement)—00
Week 24 (7 Point Improvement)—00
Week 24 (>= 8 Point Improvement)—00
EoT (up to 253 days post-baseline) (2 Point Improvement)—22
EoT (up to 253 days post-baseline) (3 Point Improvement)—22
EoT (up to 253 days post-baseline) (4 Point Improvement)—00
EoT (up to 253 days post-baseline) (5 Point Improvement)—11
EoT (up to 253 days post-baseline) (6 Point Improvement)—11
EoT (up to 253 days post-baseline) (7 Point Improvement)—22
EoT (up to 253 days post-baseline) (>= 8 Point Improvement)—00
Follow-up (up to 257 days post-baseline) (2 Point Improvement)134
Follow-up (up to 257 days post-baseline) (3 Point Improvement)011
Follow-up (up to 257 days post-baseline) (4 Point Improvement)000
Follow-up (up to 257 days post-baseline) (5 Point Improvement)000
Follow-up (up to 257 days post-baseline) (6 Point Improvement)000
Follow-up (up to 257 days post-baseline) (7 Point Improvement)000
Follow-up (up to 257 days post-baseline) (>= 8 Point Improvement)000
SecondaryChange From Baseline in Total Quantitative Myasthenia Gravis (QMG) Score Over Time

The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.

Time frame:
Baseline up to Weeks 4, 8, 12, 24, End of Treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)
Reported as:
Mean · score on a scale
Change From Baseline in Total Quantitative Myasthenia Gravis (QMG) Score Over Time
score on a scalePlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Week 41.5 ± 6.36-1.3 ± 2.60-0.8 ± 3.28
Week 8-3.0 ± 5.661.0 ± 1.530.1 ± 2.98
Week 12-0.5 ± 3.54-1.2 ± 2.23-1.0 ± 2.33
Week 24—-2.7 ± 1.53-2.7 ± 1.53
EoT (up to 253 days post-baseline)—-2.4 ± 4.12-2.4 ± 4.12
Follow-up (up to 257 days post-baseline)-3.0 ± NA-1.6 ± 2.07-1.8 ± 1.98
SecondaryChange From Baseline in Total Revised Myasthenia Gravis Quality of Life - 15 Scale (MG-QoL15r) Score Over Time

The MG-QoL15r was used to assess the participant's limitations related to living with MG. It consists of 15 questions and each of the 15 questions were rated by the participant on a 3-point scale (0= Not at all, 1= somewhat, 2=very much) based on a recall period of "over the past few weeks". The total score is the sum of the 15 question scores and ranges from 0 to 30. Higher scores indicated more limitation.

Time frame:
Baseline up to Weeks 4, 8, 12, 24, End of Treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)
Reported as:
Mean · score on a scale
Change From Baseline in Total Revised Myasthenia Gravis Quality of Life - 15 Scale (MG-QoL15r) Score Over Time
score on a scalePlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Week 41.4 ± 3.85-2.2 ± 4.53-1.6 ± 4.57
Week 8-0.4 ± 3.97-1.9 ± 4.34-1.6 ± 4.23
Week 12-1.0 ± 6.27-3.4 ± 4.70-2.9 ± 4.95
Week 24-3.0 ± NA-1.4 ± 1.52-1.7 ± 1.51
EoT (up to 253 days post-baseline)—-3.7 ± 5.28-3.7 ± 5.28
Follow-up (up to 257 days post-baseline)-1.3 ± 5.720.1 ± 3.11-0.2 ± 3.69
SecondaryChange From Baseline in Clinical Global Impression of Severity (CGI-S) Rating Score Over Time

The CGI-S scale is the clinician/physician's global assessment of participants illness severity of MG and is rated by answering on 8-point scale. Considering total clinical experience, participant is assessed on severity of illness according to: 0=not performed; 1=normal, not at all ill; 2=borderline illness; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. Higher scores indicated more severity of illness. Values of 0 (not assessed) were excluded from analysis. CGI-S permits global evaluation of participant's condition at given time.

Time frame:
Baseline up to Weeks 4, 8, 12, 24, End of Treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)
Reported as:
Mean · score on a scale
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Rating Score Over Time
score on a scalePlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Week 4-0.2 ± 0.84-0.3 ± 0.60-0.3 ± 0.63
Week 8-1.0 ± 0.71-0.6 ± 0.90-0.7 ± 0.86
Week 12-0.5 ± 1.00-0.5 ± 0.80-0.5 ± 0.81
Week 240.0 ± NA-0.6 ± 0.89-0.5 ± 0.84
EoT (up to 253 days post-baseline)—-0.7 ± 0.95-0.7 ± 0.95
Follow-up (up to 257 days post-baseline)-1.0 ± 1.22-0.1 ± 0.73-0.3 ± 0.88
SecondaryNumber of Participants With Improvement of Illness Over Time Based on Clinical Global Impression of Improvement (CGI-I) Scale Score

Number of participants with improvement of illness based on CGI-I scale score over time were reported. The CGI-I scale is the clinician/physician's global assessment of the change in severity of the patient's generalized myasthenia gravis (gMG) since starting this study. The rating is given on a 7-point scale with lower scores indicating greater improvement (1= Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 =Minimally worse; 6 = Much worse; 7 = Very much worse. Values of 0 (not assessed) were excluded from analysis. Higher score indicates more severity.

Time frame:
Weeks 4, 8, 12, 24, End of Treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)
Reported as:
Count of participants · Participants
Number of Participants With Improvement of Illness Over Time Based on Clinical Global Impression of Improvement (CGI-I) Scale Score
ParticipantsPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Week 4 (Very much worse)000
Week 4 (Much worse)000
Week 4 (Minimally worse)123
Week 4 (No change)178
Week 4 (Minimally improved)21214
Week 4 (Much improved)055
Week 4 (Very much improved)101
Week 8 (Very much worse)000
Week 8 (Much worse)000
Week 8 (Minimally worse)022
Week 8 (No change)033
Week 8 (Minimally improved)268
Week 8 (Much improved)2810
Week 8 (Very much improved)101
Week 12 (Very much worse)000
Week 12 (Much worse)000
Week 12 (Minimally worse)022
Week 12 (No change)213
Week 12 (Minimally improved)134
Week 12 (Much improved)11011
Week 12 (Very much improved)011
Week 24 (Very Much worse)000
Week 24 (Much worse)000
Week 24 (Minimally worse)000
Week 24 (No change)101
Week 24 (Minimally improved)011
Week 24 (Much improved)044
Week 24 (Very Much improved)000
EoT (up to 253 days post-baseline)(Very Much worse)—00
EoT (up to 253 days post-baseline)(Much worse)—00
EoT (up to 253 days post-baseline) (Minimally worse)—00
EoT (up to 253 days post-baseline) (No change)—11
EoT (up to 253 days post-baseline)(Minimally improved)—77
EoT (up to 253 days post-baseline)(Much improved)—77
EoT (up to 253 days post-baseline)(Very much improved)—11
Follow-up (up to 257 days post-baseline) (Very Much worse)000
Follow-up (up to 257 days post-baseline) (Much worse)123
Follow-up (up to 257 days post-baseline) (Minimally worse)033
Follow-up (up to 257 days post-baseline) (No change)055
Follow-up (up to 257 days post-baseline) (Minimally improved)088
Follow-up (up to 257 days post-baseline) (Much improved)325
Follow-up (up to 257 days post-baseline) (Very much improved)112
SecondaryNumber of Participants With Change From Baseline in Myasthenia Gravis Foundation of America (MGFA) Classification Score Over Time

Number of participants with change from baseline in MGFA classification score over time were reported. The MGFA was used to assess the participant's MG severity. MGFA classification identifies the subgroup participants with MG who share distinct clinical features or severity of disease: Class I (ocular MG), classes II, III and IV generalized MG with mild, moderate and severe disease, respectively; Class V MG crisis. Separate subclasses under classes II, III and IV are designed: "a" if the predominant weakness is affecting limb/axial weakness or both; subclass "b" if the predominant weakness is affecting oropharyngeal or respiratory muscles or both. In the MGFA classification, lower roman numerals mean less severity. Changes in MGFA classification (regardless of subclass) are categorized as "Improved" (example, III to II), "Same" (example, II to II), or "Worsened" (example, II to III).

Time frame:
Weeks 8, 24 and End of Treatment (EoT) (up to 253 days post-baseline)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Myasthenia Gravis Foundation of America (MGFA) Classification Score Over Time
ParticipantsPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Week 8 (Improved)156
Week 8 (Same)336
Week 8 (Worsened)011
Week 24 (Improved)000
Week 24 (Same)112
Week 24 (Worsened)000
EoT (up to 253 days post-baseline)(Improved)—44
EoT (up to 253 days post-baseline)(Same)—33
EoT (up to 253 days post-baseline)(Worsened)—11
SecondaryNumber of Participants With Anti-drug Antibodies (ADA) to Nipocalimab

Number of participants with ADA to nipocalimab were reported. The presence of ADA to nipocalimab in serum was determined by a sensitive and drug-tolerant electrochemiluminescence immunoassay (ECLIA) method.

Time frame:
Up to 257 days post-baseline
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADA) to Nipocalimab
ParticipantsPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Number of Participants With Anti-drug Antibodies (ADA) to Nipocalimab11617
SecondaryNumber of Participants With Neutralizing Antibodies (NAbs) to Nipocalimab

Number of participants with NAbs were reported. Neutralizing antibodies to nipocalimab were assessed using a non-cell based competitive ligand binding ECLIA assay.

Time frame:
Up to 257 days post-baseline
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Antibodies (NAbs) to Nipocalimab
ParticipantsPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Number of Participants With Neutralizing Antibodies (NAbs) to Nipocalimab044
PrimaryNumber of Participants With Below/Above Normal Values of Coagulation Laboratory Parameter

Number of participants with at least one value above upper limit of normal (\>ULN) or below the lower limit of normal (\< LLN) value of coagulation parameters (activated partial thromboplastin time \[APTT\] and prothrombin time \[PT\]) were reported. The lab reference range for APTT is 25.1 to 36.5 seconds. The lab reference range for PT is 9.4 to 12.5 seconds.

Time frame:
Up to 257 days post-baseline
Reported as:
Count of participants · Participants
Number of Participants With Below/Above Normal Values of Coagulation Laboratory Parameter
ParticipantsPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
APTT (>ULN)21517
APTT (<LLN)033
PT (>ULN)189
PT (<ULN)011
SecondaryChange From Baseline in Serum Immunoglobulin (Ig)G Concentration Over Time

Change from baseline in serum immunoglobulin (Ig)G concentration over time was reported.

Time frame:
Baseline to Weeks 2, 4, 8, 12, 24, up to 253 days post-baseline, up to 257 days post-baseline
Reported as:
Mean · g/L
Change From Baseline in Serum Immunoglobulin (Ig)G Concentration Over Time
g/LPlacebo-NipocalimabNipocalimab-NipocalimabNipocalimab (All Participants)
Week 2-6.888 ± 0.6104-5.457 ± 1.2510-5.681 ± 1.2804
Week 4-3.234 ± 1.1858-2.796 ± 0.9728-2.866 ± 1.0014
Week 8-2.996 ± 1.3773-3.122 ± 1.3466-3.095 ± 1.3235
Week 12-3.243 ± 1.6378-3.639 ± 2.2627-3.563 ± 2.1269
Week 24-3.870 ± NA-4.072 ± 1.2826-4.038 ± 1.1502
253 days post-baseline—-3.494 ± 1.9208-3.494 ± 1.9208
257 days post-baseline-1.150 ± 0.5687-0.020 ± 1.6162-0.289 ± 1.5056

Adverse events

Collected over Up to 257 days post-baseline (Day 1). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-Nipocalimab0/7 (0%)1/7 (14.3%)4/7 (57.1%)
Nipocalimab-Nipocalimab1/30 (3.3%)4/30 (13.3%)17/30 (56.7%)
Most frequent serious events
Most frequent serious events
EventPlacebo-NipocalimabNipocalimab-Nipocalimab
Covid-19 PneumoniaInfections and infestations1/70/30
Myasthenia GravisNervous system disorders0/72/30
Coronavirus InfectionInfections and infestations0/71/30
GliosarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/71/30
Most frequent other events
Showing 10 of 53
Most frequent other events
EventPlacebo-NipocalimabNipocalimab-Nipocalimab
Vertigo PositionalEar and labyrinth disorders1/70/30
ToothacheGastrointestinal disorders1/70/30
Oedema PeripheralGeneral disorders1/73/30
Blood Immunoglobulin G DecreasedInvestigations1/74/30
Hepatic Enzyme IncreasedInvestigations1/70/30
ArthralgiaMusculoskeletal and connective tissue disorders1/71/30
Myasthenia GravisNervous system disorders1/70/30
Depressed MoodPsychiatric disorders1/70/30
Rash Maculo-PapularSkin and subcutaneous tissue disorders1/70/30
DiarrhoeaGastrointestinal disorders0/72/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo-NipocalimabNipocalimab-NipocalimabTotal
<=18 years000
Between 18 and 65 years52025
>=65 years21012
Age, Continuous
Age, Continuous(years)Placebo-NipocalimabNipocalimab-NipocalimabTotal
Mean53.7 ± 20.3953 ± 16.9353.2 ± 17.33
Sex: Female, Male
Sex: Female, Male(Participants)Placebo-NipocalimabNipocalimab-NipocalimabTotal
Female41822
Male31215
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo-NipocalimabNipocalimab-NipocalimabTotal
Hispanic or Latino224
Not Hispanic or Latino52833
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo-NipocalimabNipocalimab-NipocalimabTotal
American Indian or Alaska Native000
Asian000
Black or African American011
Native Hawaiian or Other Pacific Islander000
White52934
More than one race000
Unknown or Not Reported000
Other202
Region of Enrollment
Region of Enrollment(Participants)Placebo-NipocalimabNipocalimab-NipocalimabTotal
GERMANY112
ITALY022
POLAND077
SPAIN4711
UNITED STATES21315
08

Study locations

54 sites
  • Momenta Investigational Site
    Phoenix, Arizona 85013, United States
  • Momenta Investigational Site
    Los Angeles, California 90048, United States
  • Momenta Investigational Site
    Orange, California 92868, United States
  • Momenta Investigational Site
    Stanford, California 94305, United States
  • Momenta Investigational Site
    Aurora, Colorado 80045, United States
  • Momenta Investigational Site
    New Haven, Connecticut 06511, United States
  • Momenta Investigational Site
    Boca Raton, Florida 33487, United States
  • Momenta Investigational Site
    Maitland, Florida 32751, United States
  • Momenta Investigational Site
    Port Charlotte, Florida 33952, United States
  • Momenta Investigational Site
    Saint Petersburg, Florida 33713, United States
  • Momenta Investigational Site
    Augusta, Georgia 30912, United States
  • Momenta Investigational Site
    Fairway, Kansas 66205, United States
  • Momenta Investigational Site
    Boston, Massachusetts 02114, United States
  • Momenta Investigational Site
    Boston, Massachusetts 02115, United States
  • Momenta Investigational Site
    Boston, Massachusetts 02215, United States
  • Momenta Investigational Site
    New Brunswick, New Jersey 08550, United States
  • Momenta Investigational Site
    New York, New York 10021, United States
  • Momenta Investigational Site
    Charlotte, North Carolina 28207, United States
  • Momenta Investigational Site
    Durham, North Carolina 27710, United States
  • Momenta Investigational Site
    Raleigh, North Carolina 27607, United States
  • Momenta Investigational Site
    Cincinnati, Ohio 45267, United States
  • Momenta Investigational Site
    Columbus, Ohio 43210, United States
  • Momenta Investigational Site
    Cordova, Tennessee 38106, United States
  • Momenta Investigational Site
    Austin, Texas 78756, United States
  • Momenta Investigational Site
    Round Rock, Texas 78681, United States
  • Momenta Investigational Site
    Leuven, Vlaams Brabant 3000, Belgium
  • Momenta Investigational Site
    Antwerp, 2650, Belgium
  • Momenta Investigational Site
    Bruxelles, 1070, Belgium
  • Momenta Investigational Site
    Edmonton, Alberta T6G 2G3, Canada
  • Momenta Investigational Site
    London, Ontario N6A 5A5, Canada
  • Momenta Investigational Site
    Toronto, Ontario M5G 2C4, Canada
  • Momenta Investigational Site
    Quebec City, Quebec G1J 1Z4, Canada
  • Momenta Investigational Site
    Gottingen, Niedersachsen 37075, Germany
  • Momenta Investigational Site
    Dusseldorf, 40225, Germany
  • Momenta Investigational Site
    Gummersbach, 51643, Germany
  • Momenta Investigational Site
    Munster, 48149, Germany
  • Momenta Investigational Site
    Cefalu, 90015, Italy
  • Momenta Investigational Site
    Messina, 98125, Italy
  • Momenta Investigational Site
    Milano, 20133, Italy
  • Momenta Investigational Site
    Krakow, 31-505, Poland
  • Momenta Investigational Site
    Lodz, 90-324, Poland
  • Momenta Investigational Site
    Warsaw, 01-684, Poland
  • Momenta Investigational Site
    Warsaw, 01-868, Poland
  • Momenta Investigational Site
    Barcelona, Catalan 08035, Spain
  • Momenta Investigational Site
    Barcelona, Catalan 08041, Spain
  • Momenta Investigational Site
    Barcelona, Cataluna 08036, Spain
  • Momenta Investigational Site
    L'hospitalet De Llobregat, Cataluna 08907, Spain
  • Momenta Investigational Site
    San Sebastian, Gipuzkoa 20014, Spain
  • Momenta Investigational Site
    Madrid, 28007, Spain
  • Momenta Investigational Site
    Madrid, 28040, Spain
  • Momenta Investigational Site
    Sevilla, 41013, Spain
  • Momenta Investigational Site
    Valencia, 46026, Spain
  • Momenta Investigational Site
    Birmingham, B15 2TH, United Kingdom
  • Momenta Investigational Site
    Sheffield, S11 9NE, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Dec 2020, 16 months.

Results were first posted in Feb 2022, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2019
First posted
Mar 29, 2019
StartActual
Aug 6, 2019
Primary completionActual
Dec 9, 2020
CompletionActual
Dec 9, 2020
Results first posted
Feb 16, 2022
Last update
Jun 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03896295
Responsible party
Sponsor
First posted
Mar 29, 2019
Start date
Aug 6, 2019
Primary completion
Dec 9, 2020
Completion
Dec 9, 2020
Results posted
Feb 16, 2022
Last update
Jun 27, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nipocalimab

Start the discussion